Hemostemix's Social Media Awareness of "Your Fountain of Youth"(TM) Regenerative Medicine Treatments Is Gaining Traction
Hemostemix (TSXV: HEM) (OTC: HMTXF) announces growing traction in its social media awareness campaign across multiple platforms, promoting its trademarked "Your Fountain of Youth"™ regenerative medicine treatments. The campaign shares patient success stories and educates about innovative treatments for no-option cardiovascular diseases.
The company's ACP-01 treatment, derived from patients' blood and cultured in their serum, has shown significant results:
- In dilated cardiomyopathy patients, cardiac function improved by up to 47.1% after one treatment
- For Chronic Limb Threatening Ischemia (CLTI), 83% of patients followed for up to 4.5 years experienced healing of ulcers and pain resolution
- Ulcer size decreased significantly from 1.46 cm² to 0.48 mm² within three months in phase II trials
Hemostemix (TSXV: HEM) (OTC: HMTXF) annuncia un crescente interesse nella sua campagna di sensibilizzazione sui social media su più piattaforme, promuovendo i suoi trattamenti di medicina rigenerativa registrati come "La tua Fonte della Giovinezza"™. La campagna condivide storie di successo dei pazienti e informa sui trattamenti innovativi per le malattie cardiovascolari senza opzioni terapeutiche.
Il trattamento ACP-01 dell'azienda, derivato dal sangue dei pazienti e coltivato nel loro siero, ha mostrato risultati significativi:
- Nei pazienti con cardiomiopatia dilatativa, la funzione cardiaca è migliorata fino al 47,1% dopo un trattamento
- Per l'ischemia cronica degli arti minacciata (CLTI), l'83% dei pazienti seguiti per un massimo di 4,5 anni ha sperimentato la guarigione delle ulcere e la risoluzione del dolore
- La dimensione delle ulcere è diminuita significativamente da 1,46 cm² a 0,48 mm² nell'arco di tre mesi durante le prove di fase II
Hemostemix (TSXV: HEM) (OTC: HMTXF) anuncia un creciente interés en su campaña de concienciación en redes sociales a través de múltiples plataformas, promoviendo sus tratamientos de medicina regenerativa registrados como "Tu Fuente de Juventud"™. La campaña comparte historias de éxito de pacientes y educa sobre tratamientos innovadores para enfermedades cardiovasculares sin opciones disponibles.
El tratamiento ACP-01 de la compañía, derivado de la sangre de los pacientes y cultivado en su suero, ha mostrado resultados significativos:
- En pacientes con cardiomiopatía dilatada, la función cardíaca mejoró hasta un 47,1% tras un tratamiento
- Para la Isquemia Crónica de Extremidades Amenazada (CLTI), el 83% de los pacientes seguidos durante un máximo de 4,5 años experimentaron curación de úlceras y resolución del dolor
- El tamaño de las úlceras disminuyó significativamente de 1,46 cm² a 0,48 mm² en un período de tres meses durante los ensayos de fase II
Hemostemix (TSXV: HEM) (OTC: HMTXF)는 여러 플랫폼에서 소셜 미디어 인지도 캠페인의 증가하는 관심을 발표하며, 자신의 상표 등록 의학인 "당신의 젊음의 샘"™을 홍보하고 있습니다. 이 캠페인은 환자의 성공 사례를 공유하고 선택권이 없는 심혈관 질환에 대한 혁신적인 치료법에 대해 교육합니다.
회사의 ACP-01 치료법은 환자의 혈액에서 유래되어 그들의 혈청에서 배양된 것으로, 상당한 결과를 보여주었습니다:
- 확장형 심근병증 환자에서, 치료 후 심장 기능이 최대 47.1% 개선되었습니다
- 하지의 만성 위협성 허혈(CLT) 환자의 83%가 최대 4.5년 동안 모니터링되어 궤양 치유와 통증 해소를 경험했습니다
- 2단계 시험에서 궤양의 크기가 1.46 cm²에서 0.48 mm²로 3개월 이내에 유의미하게 감소했습니다
Hemostemix (TSXV: HEM) (OTC: HMTXF) annonce un intérêt croissant pour sa campagne de sensibilisation sur les réseaux sociaux sur plusieurs plateformes, promouvant ses traitements de médecine régénérative déposés sous la marque "Votre Fontaine de Jouvence"™. La campagne partage des histoires de succès de patients et éduque sur des traitements innovants pour les maladies cardiovasculaires sans options.
Le traitement ACP-01 de l'entreprise, dérivé du sang des patients et cultivé dans leur sérum, a montré des résultats significatifs :
- Chez les patients atteints de cardiomyopathie dilatée, la fonction cardiaque s'est améliorée jusqu'à 47,1 % après un traitement
- Pour l'ischémie chronique menaçant les membres (CLTI), 83 % des patients suivis pendant jusqu'à 4,5 ans ont connu une guérison des ulcères et une résolution de la douleur
- La taille des ulcères a diminué de manière significative, passant de 1,46 cm² à 0,48 mm² en trois mois lors des essais de phase II
Hemostemix (TSXV: HEM) (OTC: HMTXF) gibt bekannt, dass die Aufmerksamkeit für seine Kampagne zur Sensibilisierung in sozialen Medien auf mehreren Plattformen zunimmt, und fördert seine markenrechtlich geschützten Behandlungen der regenerativen Medizin "Ihre Quelle der Jugend"™. Die Kampagne teilt Erfolgsgeschichten von Patienten und informiert über innovative Behandlungen für kardiovaskuläre Erkrankungen ohne Optionen.
Die ACP-01 Behandlung des Unternehmens, die aus dem Blut der Patienten gewonnen und in deren Serum kultiviert wird, hat signifikante Ergebnisse gezeigt:
- Bei Patienten mit dilatierter Kardiomyopathie verbesserte sich die Herzfunktion nach einer Behandlung um bis zu 47,1%
- Bei Patienten mit chronischer Gliedmaßenbedrohender Ischämie (CLTI) erlebten 83% der über einen Zeitraum von bis zu 4,5 Jahren beobachteten Patienten die Heilung von Geschwüren und die Auflösung von Schmerzen
- Die Größe der Geschwüre verringerte sich in den Phase-II-Studien innerhalb von drei Monaten signifikant von 1,46 cm² auf 0,48 mm²
- None.
- None.
Hemostemix is revolutionizing how individuals think about their own regenerative medicine treatments. With social media, the company is educating individuals about treatments and advancements.
Calgary, Alberta--(Newsfile Corp. - December 31, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that its social media campaign across Instagram, Facebook, LinkedIn, YouTube, and X is gaining traction. This campaign aims to share patient success stories, connect with individuals seeking safe and innovative treatments for no-option cardiovascular diseases, and educate the public about Hemostemix as an investment opportunity.
Follow Hemostemix:
- Instagram: https://www.instagram.com/hemostemix.inc?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==
- Facebook: https://www.facebook.com/profile.php?id=100087329604596
- LinkedIn: https://www.linkedin.com/company/3212019/
- YouTube: https://www.youtube.com/@hemostemix3830
- X: @heartrepairguy
Innovating Health and Restoring Quality of Life
"We trademarked "Your Fountain of Youth"™ to explain how angiogenesis works to regenerate circulation where the body signals that need," stated Thomas Smeenk, CEO. "Our social media campaign provides individuals seeking knowledge about how ACP-01 works. It is compelling to listen to the voice of the treated patient describe how ACP-01 reversed vascular dementia," Smeenk said.
ACP-01, sourced from the patient's blood and cultured in the patient's serum, is proven to be safe and statistically significant. For example:
- In dilated cardiomyopathy patients, cardiac function as measured by left ventricle ejection fraction percent (LVEF%) increased by up to
47.1% following one treatment (Stem Cell Research & Therapy, November 2023), with the most marked improvements observed in patients with severe dilated cardiomyopathy (LVEF% <20% ).
Addressing Chronic Limb Threatening Ischemia (CLTI): As compared to the five-year mortality rate of
83% of patients followed for up to 4.5 years experienced healing of ulcers and resolution of ischemic rest pain.- Additionally, the Company published its phase II results that ulcer size decreased significantly in the treated group from a mean of 1.46 cm² to 0.48 mm², p = 0.01 within three months (Journal of Biomedical Research & Environmental Science, February 2024).
About Hemostemix
Founded in 2003, Hemostemix is a clinical-stage biotechnology company and winner of the World Economic Forum Technology Pioneer Award. The Company has developed and patented a blood-based stem cell therapeutics platform that includes angiogenic cell precursors (ACP), neuronal cell precursors (NCP), and cardiomyocyte cell precursors (CCP). These treatments are designed to transform outcomes for patients with severe cardiovascular and nervous system conditions.
For more information, visit www.hemostemix.com.
For further information, please contact:
Thomas Smeenk, President & CEO
Email: tsmeenk@hemostemix.com
Phone: 905-580-4170
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to sales of its lead product ACP-01, the commercialization of ACP-01 via the sale of compassionate treatments under Special Access Program. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of the litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemis may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at www.sedarplus.ca. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/235682
FAQ
What clinical results has HMTXF's ACP-01 treatment shown for cardiomyopathy patients?
What are the success rates of HMTXF's treatment for Chronic Limb Threatening Ischemia?
How effective is HMTXF's treatment in reducing ulcer size?
What platforms is HMTXF using for its social media awareness campaign?
What is the source material for HMTXF's ACP-01 treatment?
